产品名称
雷夫康唑, ≥97% (NMR)
SMILES string
Fc1c(ccc(c1)F)[C@](O)([C@@H](C)c3[s]cc(n3)c4ccc(cc4)C#N)C[n]2ncnc2
InChI
1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-7-6-17(23)8-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1
InChI key
OPAHEYNNJWPQPX-RCDICMHDSA-N
assay
≥97% (NMR)
form
powder
optical activity
[α]/D -27 to -33°, c = 1 in methanol
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
Quality Level
相关类别
Biochem/physiol Actions
Ravuconazole (BMS-207147) is a potent and broad spectrum triazole antifungal. Ravuconazole is an inhibitor of sterol biosynthesis by inhibition of cytochrome P450 14α-demethylase, an enzyme in the sterol biosynthesis pathway that leads from lanosterol to ergosterol.
Ravuconazole is a potent and broad spectrum triazole antifungal.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Yara Almeida Machado et al.
Antimicrobial agents and chemotherapy, 64(8) (2020-05-20)
Mining existing agents that enhance the therapeutic potential of ergosterol biosynthesis inhibitors (EBI) is a promising approach to improve Chagas disease chemotherapy. In this study, we evaluated the effect of ravuconazole, an EBI, combined with amlodipine, a calcium channel blocker
Pollyanna Álvaro Spósito et al.
International journal of nanomedicine, 12, 3785-3799 (2017-05-30)
Self-emulsifying drug delivery systems (SEDDSs) are lipid-based anhydrous formulations composed of an isotropic mixture of oil, surfactant, and cosurfactants usually presented in gelatin capsules. Ravuconazole (Biopharmaceutics Classification System [BCS] Class II) is a poorly water-soluble drug, and a SEDDS type
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持